title: [Antibody therapy in hematology and oncology - part 1].
authors.affiliation: II. Medizinische Klinik und Poliklinik, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany. sekretariat@med2.uni-kiel.de
authors.forename: Michael
authors.initials: M
authors.lastname: Kneba
authors.forename: Carsten
authors.initials: C
authors.lastname: Schrader
authors.forename: Henning
authors.initials: H
authors.lastname: Köhne
mesh_terms: D000368:Aged; D000074323:Alemtuzumab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy* / Q000532:radiotherapy; D008224:Lymphoma, Follicular / Q000188:drug therapy; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D008297:Male; D051379:Mice; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use; D016499:Radioimmunotherapy; D012074:Remission Induction; D000069283:Rituximab; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone